Arcturus Therapeutics Analyst Price Targets - Benzinga

SPY778.57+0.60%QQQ751.38+0.51%BTC/USD83,802.40+1.06%DIA516.21+0.89%GLD384.50+1.55%TLT77.97+0.12%

Arcturus Therapeutics Holdings Inc

ARCTNASDAQ

Trade with Public

Trade with Public

$13.74

0.876.76%

Last update: Oct 9, 4:00 PM

$13.05

0.181.4%

Overview News Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Compare Options Stock Report

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell

© 2026 Benzinga | All Rights Reserved

Arcturus Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Arcturus Therapeutics (ARCT).

Price Target Range — 12 Quarters

Analyst Consensus — 11 Analysts

9Buy

2Hold

Consensus RatingBuy# Analysts11Avg. Consensus PT$31Upside to Avg. PT+126.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 9, 2026	Leerink Partners	Lili Nsongo	PT Raise	Outperform	$13→$19
Sep 24, 2026	Citigroup	Yigal Nochomovitz	Upgrade	Neutral→Buy	$8→$20
Sep 24, 2026	BTIG	Thomas Shrader	PT Cut	Buy	$23→$20
Jul 2, 2026	Freedom Broker	Ilya Zubkov	Initiate	Buy	$27
Mar 18, 2026	B. Riley Securities	Mayank Mamtani	Initiate	Neutral→Buy	$22
Mar 5, 2026	Citigroup	Whitney Ijem	PT Cut	Buy	$66→$21
Mar 4, 2026	Citigroup	Yigal Nochomovitz	PT Raise	Neutral	$7→$8
Mar 4, 2026	Piper Sandler	Yasmeen Rahimi	PT Cut	Overweight	$72→$25
Jan 6, 2026	Citigroup	Yigal Nochomovitz	PT Cut	Neutral	$9→$7
Nov 13, 2025	Citigroup	Yigal Nochomovitz	PT Cut	Neutral	$12→$9
Nov 11, 2025	Piper Sandler	Yasmeen Rahimi	PT Cut	Overweight	$140→$72
Nov 11, 2025	HC Wainwright & Co.	Andrew S. Fein	PT Cut	Neutral	$12→$9
Oct 24, 2025	HC Wainwright & Co.	Andrew S. Fein	Downgrade	Buy→Neutral	$60→$12
Oct 23, 2025	Citigroup	Yigal Nochomovitz	Downgrade	Buy→Neutral	$49→$12
Oct 23, 2025	Wells Fargo	Yanan Zhu	PT Cut	Overweight	$42→$20
Oct 23, 2025	Guggenheim	Seamus Fernandez	Downgrade	Buy→Neutral	—
Oct 22, 2025	BTIG	Thomas Shrader	PT Cut	Buy	$48→$23
Oct 22, 2025	Guggenheim	Seamus Fernandez	Downgrade	Buy→Neutral	—
Sep 4, 2025	HC Wainwright & Co.	Andrew S. Fein	Assumes	Buy	$60
Aug 22, 2025	Leerink Partners	Lili Nsongo	PT Cut	Outperform	$63→$54

More with Benzinga EdgeGet Access

Analyst Ratings News

CrowdStrike To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Friday

Analysts raised targets for HOOD, SAIL, U and CRWD; cut targets for BULL, ALGN and PCRX, with PCRX downgraded to Neutral.

Avi Kapoor

PRO
Leerink Partners Maintains Outperform on Arcturus Therapeutics, Raises Price Target to $19

Leerink Partners analyst Lili Nsongo maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Outperform and raises the price target from $13 to $19.

Benzinga Newsdesk

PRO
Citigroup Upgrades Arcturus Therapeutics to Buy, Raises Price Target to $20

Citigroup analyst Yigal Nochomovitz upgrades Arcturus Therapeutics (NASDAQ:ARCT) from Neutral to Buy and raises the price target from $8 to $20.

Benzinga Newsdesk

PRO
BTIG Maintains Buy on Arcturus Therapeutics, Lowers Price Target to $20

BTIG analyst Thomas Shrader maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Buy and lowers the price target from $23 to $20.

Benzinga Newsdesk

This Adobe Analyst Turns Bullish; Here Are Top 4 Upgrades For Thursday

Top analysts upgraded Palantir, Silicom, Adobe, and Chevron. See what other analysts think about these stocks. Photo via Shutterstock.

Avi Kapoor

This Honeywell Aerospace Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Wall Street analysts change outlook on top names. Check analyst ratings page for all changes. Consider buying HONA stock - analysts' thoughts.

Avi Kapoor